SAN DIEGO, CA / ACCESSWIRE / June 8, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce the beginning of enrollment of the second cohort in dosing patients for its Phase I trial for Brain Cancer. This milestone allows the trial to triple the dosage levels over the first cohort to achieve the highest level without toxicity.

Patient enrollment continues for Phase I. Anyone interested may review trial requirements at www.clinicaltrials.gov, then search Pritumumab.

"Having completed the first cohort in a very short time, we are now in our second dose escalation with the second cohort being enrolled," noted Nascent CEO, Sean Carrick.

PTB is a natural human antibody that works by binding to Cell surface Vimentin (also referred to as ectodomain vimentin, or EDV), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy unlike chemotherapy targets only cancer cells without damaging healthy cells."

About Nascent Biotech

Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping people worldwide. Its products are not yet commercially available. The Company's lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that is being studied in Phase I clinical trials for the treatment of Brain Cancer. Development for PTB as a treatment for COVID-19 has been initiated.

For further information please visit our website www.nascentbiotech.com.

Forward Looking Safe Harbor Statement

Statements in this press release about our future expectations constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Corporate Contact
Sean Carrick | President | CEO
Nascent Biotech, Inc.
772.713.0541 Cell | sean.carrick@nascentbiotech.com

Public Relations
EDM Media, LLC
https://edm.media
(800) 301-7883

SOURCE: Nascent Biotech Inc.